A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor

GSK Investigational Site, New York

GSK Investigational Site, Berlin

GSK Investigational Site, Tallinn

GSK Investigational Site, Marseille

GSK Investigational Site, Philadelphia

GSK Investigational Site, Newark

GSK Investigational Site, Großhansdorf

GSK Investigational Site, Montpellier

GSK Investigational Site, Immenhausen

GSK Investigational Site, Velbert

GSK Investigational Site, Herne

GSK Investigational Site, Moers

GSK Investigational Site, Münster

GSK Investigational Site, Tartu

GSK Investigational Site, Cologne

GSK Investigational Site, Rochester

GSK Investigational Site, Springfield

GSK Investigational Site, Heidelberg

GSK Investigational Site, Lyon

GSK Investigational Site, Munich

GSK Investigational Site, Créteil

GSK Investigational Site, Seattle

GSK Investigational Site, Everett

GSK Investigational Site, Saint Petersburg

GSK Investigational Site, Chelyabinsk

GSK Investigational Site, Paterson

GSK Investigational Site, Hyōgo

GSK Investigational Site, Kanagawa

GSK Investigational Site, Kanagawa

GSK Investigational Site, Shizuoka

GSK Investigational Site, Szczecin

GSK Investigational Site, Zakopane

GSK Investigational Site, Saint Petersburg

GSK Investigational Site, Seoul

GSK Investigational Site, Cambridge

GSK Investigational Site, Edinburgh

GSK Investigational Site, Birmingham

GSK Investigational Site, Manchester

GSK Investigational Site, Sheffield